Daily Endocrinology Research Analysis
Analyzed 26 papers and selected 3 impactful papers.
Summary
A β cell–targeted lipid nanoparticle mRNA platform demonstrated disease-modifying potential in preclinical type 1 diabetes by inducing PD-L1 in β cells and delaying diabetes onset. Electronic health record–based subtyping of 727,076 newly diagnosed type 2 diabetes cases stratified risks for micro- and macrovascular complications. A meta-analysis of nearly 4 million patients associated GLP-1 receptor agonist use with lower risks of multiple obesity-related cancers within 10 years.
Research Themes
- β cell–targeted nucleic acid therapeutics for type 1 diabetes
- EHR-driven precision subtyping of type 2 diabetes and vascular risk
- Onco-metabolic effects of incretin-based therapies
Selected Articles
1. Messenger RNA delivery to islet β cells using conjugated lipid nanoparticles.
A β cell–enriched LNP platform, further targeted by eGLP-1 conjugation, enabled efficient mRNA delivery to mouse and human β cells. In prediabetic NOD mice, PD-L1 mRNA delivery reduced insulitis and delayed autoimmune diabetes; delivery to human β cells was also shown in vivo in a xenotransplant model.
Impact: This establishes a tractable, β cell–targeted nucleic acid delivery platform with disease-modifying effects in a T1D model, bridging a key translational gap for immune-modulatory cell-specific therapies.
Clinical Implications: While preclinical, β cell–directed mRNA delivery (e.g., PD-L1) could enable localized immunomodulation to delay or prevent T1D, supporting progression toward early-phase clinical trials and companion biodistribution biomarkers.
Key Findings
- eGLP-1–conjugated LNPs enhanced pancreatic and β cell enrichment in vivo compared with unconjugated LNPs.
- PD-L1 mRNA delivery to β cells attenuated insulitis and delayed autoimmune diabetes onset in prediabetic NOD mice.
- LNPs delivered mRNA to human β cells in an in vivo xenogeneic islet transplantation model.
Methodological Strengths
- Multi-system validation including in vitro mouse/human β cells, in vivo mouse biodistribution, and human islet xenografts.
- Functional disease modification demonstrated in a relevant autoimmune T1D mouse model.
Limitations
- Preclinical evidence; no human clinical efficacy or safety data.
- Species-specific targeting advantages (eGLP-1–LNP β cell enrichment) may not fully generalize to humans.
Future Directions: Advance to GLP-1–guided LNP biodistribution studies in large animals and first-in-human safety/pharmacodynamics, with exploration of additional tolerogenic or cytoprotective mRNA cargos.
Effective therapies for type 1 diabetes (T1D) must both restrain immune hyperactivity and reduce β cell susceptibility to destruction. We describe a lipid nanoparticle (LNP) platform for β cell-enriched mRNA delivery that can be further augmented by conjugation to enhanced glucagon-like peptide-1 (eGLP-1). Both unconjugated and eGLP-conjugated LNPs deliver mRNA efficiently to mouse and human β cells in vitro. Biodistribution studies in C57BL/6J mice in vivo demonstrate pancreatic enrichment of LNPs, with greater β cell enrichment achieved by eGLP-LNPs specifically in mice. In prediabetic NOD mice, LNP delivery of PD-L1 mRNA induces β cell PD-L1 expression, attenuates insulitis, and delays the onset of autoimmune diabetes. Importantly, we find that LNPs also deliver mRNA to human β cells in a xenogeneic islet transplantation model in vivo. Together, these findings establish a versatile and translationally relevant LNP platform for β cell-directed mRNA delivery and immune modulation in T1D.
2. Subtypes of newly diagnosed type 2 diabetes and risk of complications: analysis of electronic health records in the USA.
Using EHR data from 727,076 newly diagnosed adults with type 2 diabetes across the USA, routine clinical variables classified patients into established subtypes with distinct vascular risk profiles. Severe insulin-deficient diabetes carried substantially higher hazards for micro- and macrovascular complications than mild obesity-related diabetes.
Impact: This large-scale, practice-embedded classification demonstrates that EHR-based subtypes predict differential complication risks, enabling pragmatic risk stratification at diagnosis without specialized testing.
Clinical Implications: EHR-driven subtyping could guide early surveillance and individualized targets (e.g., retinopathy screening intensity, cardiometabolic therapy) for high-risk SIDD patients versus MOD.
Key Findings
- Among 727,076 incident T2D patients, 21.6% were SIDD, 23.8% MOD, 40.9% MARD, and 13.7% mixed subtype.
- Compared with MOD, SIDD showed higher hazard for retinopathy (HR 2.83), neuropathy (HR 1.57), nephropathy (HR 1.34), severe ASCVD (HR 1.49), other ASCVD (HR 1.23), and heart failure (HR 1.17).
- SIDD and MOD were more prevalent among Hispanic and non-Hispanic Black populations than non-Hispanic White populations.
Methodological Strengths
- Very large, nationwide EHR cohort with standardized modeling and adjusted Cox analyses.
- Use of routine clinical variables enables external validity and practical implementation.
Limitations
- Retrospective design with potential residual confounding and misclassification in EHR-derived outcomes.
- Subtype assignment relies on prior models and may vary with data completeness across sites.
Future Directions: Prospective validation of EHR-based subtyping tied to tailored interventions and clinical decision support; assessment of cost-effectiveness and health equity impacts.
AIMS/HYPOTHESIS: Data-driven subtyping of type 2 diabetes has not been translated into clinical practice due to the lack of routine fasting glucose and insulin measurements. We aimed to identify type 2 diabetes subtypes in clinical settings using electronic health records and study their epidemiology. METHODS: We identified 727,076 adults (≥18 years) with newly diagnosed type 2 diabetes from Epic Cosmos research platform data across all 50 states and the District of Columbia between 2012 and 2023. Classification models developed in cohort studies were applied to study the sociodemographic distribution of subtypes. Cox proportional hazards regression models, adjusted for age and sex, were used to assess the rates of microvascular complications (retinopathy, neuropathy and nephropathy) and macrovascular complications (severe atherosclerotic cardiovascular disease [ASCVD], other ASCVD and heart failure). RESULTS: Among newly diagnosed individuals (mean age 64.4 years [SD 13.3], 52% female), 21.6% were classified as having severe insulin-deficient diabetes (SIDD), 23.8% were classified as having mild obesity-related diabetes (MOD), 40.9% were classified as having mild age-related diabetes and 13.7% were classified as having the mixed subtype. Compared with those classified as having MOD, individuals classified as having SIDD had higher HRs for retinopathy (HR 2.83; 95% CI 2.73, 2.93), neuropathy (HR 1.57; 95% CI 1.54, 1.60), nephropathy (HR 1.34; 95% CI 1.32, 1.37), severe ASCVD (HR 1.49; 95% CI 1.46, 1.53), other ASCVD (HR 1.23; 95% CI 1.21, 1.25) and heart failure (HR 1.17; 95% CI 1.15, 1.20). SIDD and MOD were more prevalent among Hispanics (28.4% and 30.1%, respectively) and non-Hispanic Black people (25.5% and 30.0%, respectively) compared with non-Hispanic White people (20.1% and 21.6%, respectively), and were also more prevalent in the District of Columbia and Utah, respectively, compared with the rest of the country. CONCLUSIONS/INTERPRETATION: Individuals with different type 2 diabetes subtypes, identified through electronic health records, differ in terms of their risk of vascular complications. These findings support leveraging routine electronic health record data to improve the characterisation of patient heterogeneity at the time of diabetes diagnosis.
3. Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis.
Across 24 studies including 3.96 million adults, GLP-1RA therapy was associated with a 30% lower overall risk of obesity-related cancers within 10 years, with reductions across several sites (e.g., liver, colorectal, pancreatic, endometrial). No significant association was found for thyroid cancer.
Impact: This synthesis connects incretin therapy to potential long-term cancer risk reduction across multiple obesity-linked malignancies, informing benefit–risk discussions for widespread GLP-1RA use.
Clinical Implications: For patients with obesity and/or T2DM, GLP-1RAs may offer ancillary cancer risk benefits; clinicians should contextualize these data alongside metabolic efficacy and evolving safety evidence, while awaiting prospective confirmation.
Key Findings
- Meta-analysis of 24 studies (n=3,960,974) showed GLP-1RA use associated with reduced overall obesity-related cancer risk within 10 years (RR 0.70, 95% CI 0.54–0.89).
- Risk reductions observed for hepatocellular carcinoma, colorectal, pancreatic, endometrial, esophageal, gallbladder, ovarian cancers, and multiple myeloma.
- No significant association was detected for thyroid cancer risk.
Methodological Strengths
- Comprehensive search across multiple databases with very large aggregate sample size.
- Site-specific analyses enabled assessment across a broad spectrum of obesity-related cancers.
Limitations
- Predominance of observational data introduces residual confounding and potential time-related biases.
- Heterogeneity in study designs, exposure definitions, and follow-up limits causal inference.
Future Directions: Prospective, adequately powered studies and mechanistic investigations to validate associations, assess duration–dose effects, and clarify causality across cancer sites.
BACKGROUND: Type 2 diabetes mellitus (T2DM) and obesity are increasing and are established risk factors for malignancy. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for T2DM and obesity, but their association with cancer risk remains uncertain. We assessed the association between GLP-1RA use and obesity-related cancers. METHODS: We searched Embase, PubMed, and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to 20 November 2025. Observational studies and randomized controlled trials of adults (≥18 years) with T2DM and/or obesity reporting cancer risk after GLP-1RA or glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor co-agonist use were included. Obesity-related cancers comprised uterine, esophageal, thyroid, gastric, colorectal, liver, gallbladder, pancreatic, breast, ovarian, kidney cancers, cholangiocarcinoma, meningioma, and multiple myeloma. FINDINGS: Twenty-four studies involving 3,960,974 patients were included. GLP-1RA use was associated with a significantly lower overall risk of obesity-related cancers within ten years (RR 0·70, 95% CI 0·54-0·89). Reduced risks were observed for hepatocellular carcinoma, colorectal, pancreatic, endometrial, esophageal, gallbladder, ovarian cancers, and multiple myeloma, with no significant association for thyroid cancer. INTERPRETATION: GLP-1RA use is associated with a lower risk of several obesity-related cancers. Prospective studies are required to validate these findings and clarify underlying mechanisms.